Neurocentrx Closes Seed Extension Round Including Funding from the Wellcome Trust
Will Provide Funding for Clinical Trials of Neurocentrx’s Novel Ketamine Prescription Option for Clinic-to-Home Based Care Wellcome Investment for a Phase 2 Trial in Bipolar Depression Starting in 2026 Company is Pursuing Series A Investment for Ph...